Paul J Van Diest

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7495864/publications.pdf

Version: 2024-02-01

324 papers 11,458 citations

51 h-index 89 g-index

328 all docs 328 docs citations

times ranked

328

14528 citing authors

#	Article	IF	CITATIONS
1	Clinical significance and molecular annotation of cellular morphometric subtypes in lower-grade gliomas discovered by machine learning. Neuro-Oncology, 2023, 25, 68-81.	0.6	18
2	Interlaboratory Gleason grading variation affects treatment: a Dutch historic cohort study in 30 509 patients with prostate cancer. Journal of Clinical Pathology, 2023, 76, 690-697.	1.0	2
3	Blunt duct adenosis: a separate entity from columnar cell lesions?. Journal of Clinical Pathology, 2022, 75, 5-9.	1.0	4
4	Grading of invasive breast carcinoma: the way forward. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 33-43.	1.4	31
5	Validation of digital microscopy: Review of validation methods and sources of bias. Veterinary Pathology, 2022, 59, 26-38.	0.8	4
6	Lack of association between CDKN2A germline mutations and survival in patients with melanoma: A retrospective cohort study. Journal of the American Academy of Dermatology, 2022, 87, 479-482.	0.6	6
7	Artificial intelligence applied to breast pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 191-209.	1.4	29
8	Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation. Advances in Radiation Oncology, 2022, 7, 100854.	0.6	3
9	Prognosis of pregnancy-associated breast cancer: inferior outcome in patients diagnosed during second and third gestational trimesters and lactation. Breast Cancer Research and Treatment, 2022, 192, 175-189.	1.1	6
10	Superficial basal cell carcinoma, think deeper: Step sectioning of skin biopsy specimens yields 14% more aggressive subtypes. PLoS ONE, 2022, 17, e0256149.	1.1	1
11	The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15Âmm in thickness). Journal of the American Academy of Dermatology, 2022, 87, 298-305.	0.6	3
12	Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium. Gynecologic Oncology, 2022, 165, 114-120.	0.6	6
13	OUP accepted manuscript. Clinical Chemistry, 2022, , .	1.5	5
14	Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer. Gynecologic Oncology, 2022, 165, 257-263.	0.6	3
15	Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. European Journal of Cancer, 2022, 167, 133-141.	1.3	3
16	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. European Journal of Cancer, 2022, 167, 123-132.	1.3	4
17	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. Journal of Clinical Oncology, 2022, 40, 2361-2374.	0.8	45
18	Spatial collagen stiffening promotes collective breast cancer cell invasion by reinforcing extracellular matrix alignment. Oncogene, 2022, 41, 2458-2469.	2.6	47

#	Article	IF	Citations
19	Intraoperative MET-receptor targeted fluorescent imaging and spectroscopy for lymph node detection in papillary thyroid cancer: novel diagnostic tools for more selective central lymph node compartment dissection. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3557-3570.	3.3	7
20	Nipple Aspirate Fluid at a Glance. Cancers, 2022, 14, 159.	1.7	7
21	Cyclic activity of signal transduction pathways in fimbrial epithelium of the human fallopian tube. Acta Obstetricia Et Gynecologica Scandinavica, 2022, 101, 256-264.	1.3	2
22	Interâ€observer agreement for the histological diagnosis of invasive lobular breast carcinoma. Journal of Pathology: Clinical Research, 2022, 8, 191-205.	1.3	19
23	Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer. Oncogene, 2022, 41, 2932-2944.	2.6	10
24	Implementation of Artificial Intelligence in Diagnostic Practice as a Next Step after Going Digital: The UMC Utrecht Perspective. Diagnostics, 2022, 12, 1042.	1.3	10
25	Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature. Breast Cancer Research and Treatment, 2022, , .	1.1	2
26	Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?. BMC Cancer, 2022, 22, .	1.1	0
27	Rocky road to digital diagnostics: implementation issues and exhilarating experiences. Journal of Clinical Pathology, 2021, 74, 415-420.	1.0	19
28	Detection of breast cancer precursor lesions by autofluorescence ductoscopy. Breast Cancer, 2021, 28, 119-129.	1.3	8
29	Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. British Journal of Surgery, 2021, 108, 550-553.	0.1	7
30	Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017. International Journal of Cancer, 2021, 148, 2289-2303.	2.3	34
31	Patient-reported outcomes of ductoscopy procedures for pathologic nipple discharge. Breast Cancer, 2021, 28, 471-477.	1.3	3
32	Tumor-Infiltrating Lymphocytes in Low-Risk Patients With Breast Cancer Treated With Single-Dose Preoperative Partial Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1325-1331.	0.4	11
33	Socioeconomic status significantly contributes to the likelihood of immediate postmastectomy breast reconstruction in the Netherlands: A nationwide study. European Journal of Surgical Oncology, 2021, 47, 245-250.	0.5	7
34	Elastosis in ERα-positive male breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 257-263.	1.4	2
35	Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. Breast Cancer Research and Treatment, 2021, 185, 817-830.	1.1	2
36	The increasing importance of histologic grading in tailoring adjuvant systemic therapy in 30,843 breast cancer patients. Breast Cancer Research and Treatment, 2021, 187, 577-586.	1.1	4

#	Article	IF	CITATIONS
37	Pregnancy-associated breast cancer: nationwide Dutch study confirms a discriminatory aggressive histopathologic profile. Breast Cancer Research and Treatment, 2021, 186, 699-704.	1.1	21
38	Deep learning-based grading of ductal carcinoma in situ in breast histopathology images. Laboratory Investigation, 2021, 101, 525-533.	1.7	20
39	Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. JAMA Dermatology, 2021, 157, 166.	2.0	21
40	Heterogeneity in Signaling Pathway Activity within Primary and between Primary and Metastatic Breast Cancers, 2021, 13, 1345.	1.7	2
41	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Annals of Oncology, 2021, 32, 375-383.	0.6	25
42	Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. Journal of Clinical Oncology, 2021, 39, 1243-1252.	0.8	28
43	Predicting sentinel node positivity in patients with melanoma: external validation of a riskâ€prediction calculator (the Melanoma Institute Australia nomogram) using a large European populationâ€based patient cohort*. British Journal of Dermatology, 2021, 185, 412-418.	1.4	14
44	High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment. European Journal of Cancer, 2021, 149, 105-113.	1.3	4
45	Can automatic image analysis replace the pathologist in cardiac allograft rejection diagnosis?. European Heart Journal, 2021, 42, 2370-2372.	1.0	2
46	Supplemental Breast MRI for Women with Extremely Dense Breasts: Results of the Second Screening Round of the DENSE Trial. Radiology, 2021, 299, 278-286.	3.6	66
47	Cytoplasmic DDX3 as prognosticator in male breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 647-655.	1.4	6
48	Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients. Journal of the National Cancer Institute, 2021, 113, 1506-1514.	3.0	6
49	In Reply to Tsoutsou. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1251-1252.	0.4	0
50	Reducing False-Positive Screening MRI Rate in Women with Extremely Dense Breasts Using Prediction Models Based on Data from the DENSE Trial. Radiology, 2021, 301, 283-292.	3.6	9
51	Meta-analysis and cost-effectiveness of ductoscopy, duct excision surgery and MRI for the diagnosis and treatment of patients with pathological nipple discharge. Breast Cancer Research and Treatment, 2021, 186, 285-293.	1.1	7
52	The changing microRNA landscape by color and cloudiness: a cautionary tale for nipple aspirate fluid biomarker analysis. Cellular Oncology (Dordrecht), 2021, 44, 1339-1349.	2.1	4
53	Receptor status of breast cancer diagnosed during pregnancy: A literature review. Critical Reviews in Oncology/Hematology, 2021, 168, 103494.	2.0	5
54	Significant Inter- and Intralaboratory Variation in Gleason Grading of Prostate Cancer: A Nationwide Study of 35,258 Patients in The Netherlands. Cancers, 2021, 13, 5378.	1.7	12

#	Article	IF	CITATIONS
55	Lessons Learned from Setting Up a Prospective, Longitudinal, Multicenter Study with Women at High Risk for Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 441-449.	1.1	10
56	Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis. Cancers, 2021, 13, 5694.	1.7	41
57	Significant inter―and intraâ€laboratory variation in grading of invasive breast cancer: A nationwide study of 33,043 patients in the Netherlands. International Journal of Cancer, 2020, 146, 769-780.	2.3	37
58	Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labellingâ€based or mitotic activity indexâ€based proliferation assessment. Histopathology, 2020, 76, 650-660.	1.6	7
59	Thick melanomas without lymph node metastases: A forgotten group with poor prognosis. European Journal of Surgical Oncology, 2020, 46, 918-923.	0.5	4
60	Tumor Response After Neoadjuvant Magnetic Resonance Guided Single Ablative Dose Partial Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2020, 106, 821-829.	0.4	38
61	Desmoplastic melanoma: The role of pure and mixed subtype in sentinel lymph node biopsy and survival. Cancer Medicine, 2020, 9, 671-677.	1.3	13
62	<i>USP6</i> -Associated Neoplasms: A Rapidly Expanding Family of Lesions. International Journal of Surgical Pathology, 2020, 28, 816-825.	0.4	42
63	The Physiological MicroRNA Landscape in Nipple Aspirate Fluid: Differences and Similarities with Breast Tissue, Breast Milk, Plasma and Serum. International Journal of Molecular Sciences, 2020, 21, 8466.	1.8	4
64	Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in <i>de novo</i> stage IV breast cancer patients: study protocol of the i-GO study. BMJ Open, 2020, 10, e040162.	0.8	19
65	Digital pathology in the time of corona. Journal of Clinical Pathology, 2020, 73, 706-712.	1.0	23
66	Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. Breast Cancer Research and Treatment, 2020, 183, 759-770.	1.1	16
67	Grading variation in 2,934 patients with ductal carcinoma in situ of the breast: the effect of laboratory- and pathologist-specific feedback reports. Diagnostic Pathology, 2020, 15, 52.	0.9	6
68	Network Meta-analysis for the Diagnostic Approach to Pathologic Nipple Discharge. Clinical Breast Cancer, 2020, 20, e723-e748.	1.1	11
69	Segmentation and Classification of Melanoma and Nevus in Whole Slide Images. , 2020, , .		7
70	Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in earlyâ€stage luminal breast cancer. Histopathology, 2020, 77, 579-587.	1.6	10
71	Methylation Profile of X-Chromosome–Related Genes in Male Breast Cancer. Frontiers in Oncology, 2020, 10, 784.	1.3	8
72	Quantifying the Mitigating Effects of Whole-Breast Radiotherapy and Systemic Treatments on Regional Recurrence Incidence Among Breast Cancer Patients. Annals of Surgical Oncology, 2020, 27, 3402-3411.	0.7	5

#	Article	IF	CITATIONS
73	Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast. Journal of Clinical Pathology, 2020, 73, 204-208.	1.0	4
74	Breast Cancer and Major Deviations of Genetic and Gender-related Structures and Function. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3065-e3074.	1.8	4
75	Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging. Theranostics, 2020, 10, 2436-2452.	4.6	32
76	Variation in breast cancer grading: the effect of creating awareness through laboratory-specific and pathologist-specific feedback reports in 16 734 patients with breast cancer. Journal of Clinical Pathology, 2020, 73, 793-799.	1.0	9
77	Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. Journal of Controlled Release, 2020, 323, 269-281.	4.8	49
78	Patients' perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict. Breast Cancer Research and Treatment, 2020, 182, 107-115.	1.1	2
79	The effect of an e-learning module on grading variation of (pre)malignant breast lesions. Modern Pathology, 2020, 33, 1961-1967.	2.9	10
80	Intraâ€nodal nevi in sentinel nodeâ€negative patients with cutaneous melanoma does not influence survival. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2291-2295.	1.3	7
81	Being fully digital: perspective of a Dutch academic pathology laboratory. Histopathology, 2019, 75, 621-635.	1.6	65
82	Sex matters: men with melanoma have a worse prognosis than women. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2062-2067.	1.3	28
83	Comparison of Survival Between Patients With Single vs Multiple Primary Cutaneous Melanomas. JAMA Dermatology, 2019, 155, 1049.	2.0	20
84	ASO Author Reflections: Sentinel Lymph Node Biopsy Trend in Melanoma: The More the Merrier. Annals of Surgical Oncology, 2019, 26, 723-724.	0.7	0
85	Stereotactic 9-gauge vacuum-assisted breast biopsy, how many specimens are needed?. European Journal of Radiology, 2019, 120, 108665.	1.2	9
86	Pathology Image Exchange: The Dutch Digital Pathology Platform for Exchange of Whole-Slide Images for Efficient Teleconsultation, Telerevision, and Virtual Expert Panels. JCO Clinical Cancer Informatics, 2019, 3, 1-7.	1.0	16
87	The Changing Role of Gene-Expression Profiling in the Era of De-escalating Adjuvant Chemotherapy in Early-Stage Breast Cancer. Annals of Surgical Oncology, 2019, 26, 3495-3501.	0.7	7
88	Probability of sentinel lymph node positivity in melanoma. European Journal of Cancer, 2019, 116, 10-12.	1.3	2
89	Re: The Association Between Hysterectomy and Ovarian Cancer Risk: A Population-Based Record-Linkage Study. Journal of the National Cancer Institute, 2019, 111, 1361-1361.	3.0	0
90	An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nature Medicine, 2019, 25, 838-849.	15.2	486

#	Article	IF	CITATIONS
91	Clinical versus histological grading in the assessment of cutaneous graft versus host disease. European Journal of Medical Research, 2019, 24, 19.	0.9	10
92	Early detection of changes in phospholipid metabolism during neoadjuvant chemotherapy in breast cancer patients using phosphorus magnetic resonance spectroscopy at 7T. NMR in Biomedicine, 2019, 32, e4086.	1.6	20
93	Predicting breast tumor proliferation from whole-slide images: The TUPAC16 challenge. Medical Image Analysis, 2019, 54, 111-121.	7.0	182
94	Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma. Annals of Surgical Oncology, 2019, 26, 1494-1502.	0.7	25
95	Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands. Breast Cancer Research and Treatment, 2019, 175, 487-497.	1.1	15
96	Application of Nipple Aspirate Fluid miRNA Profiles for Early Breast Cancer Detection and Management. International Journal of Molecular Sciences, 2019, 20, 5814.	1.8	6
97	Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. New England Journal of Medicine, 2019, 381, 2091-2102.	13.9	388
98	Unique Case of a Rare Mesenchymal Tumor Harboring a Somatic c.119delC VHL Mutation. JCO Precision Oncology, 2019, 3, 1-8.	1.5	0
99	Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands. Breast Cancer Research and Treatment, 2019, 174, 479-488.	1.1	30
100	Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases. Clinical and Experimental Metastasis, 2019, 36, 29-37.	1.7	47
101	Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33. Translational Oncology, 2019, 12, 96-105.	1.7	31
102	Heterogeneity in signaling pathway activity within primary breast cancer and between primary and metastases Journal of Clinical Oncology, 2019, 37, 589-589.	0.8	3
103	Promoter hypermethylation in ductal carcinoma in situ of the male breast. Endocrine-Related Cancer, 2019, 26, 575-584.	1.6	8
104	The molecular genetic make-up of male breast cancer. Endocrine-Related Cancer, 2019, 26, 779-794.	1.6	27
105	Assessment of <scp>HER</scp> 2 status in breast cancer biopsies is not affected by accelerated tissue processing. Histopathology, 2018, 73, 81-89.	1.6	5
106	Inflammatory breast cancer: The pathologists' perspective. European Journal of Surgical Oncology, 2018, 44, 1128-1134.	0.5	16
107	Rapid on-site evaluation during endoscopic ultrasoundguided fine-needle aspiration of lymph nodes does not increase diagnostic yield: A randomized, multicenter trial. American Journal of Gastroenterology, 2018, 113, 677-685.	0.2	33
108	Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. Cancer Research, 2018, 78, 3112-3121.	0.4	57

#	Article	IF	Citations
109	Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study. European Journal of Cancer, 2018, 90, 92-101.	1.3	13
110	Copy number profiling of oncogenes in ductal carcinoma in situ of the male breast. Endocrine-Related Cancer, 2018, 25, 173-184.	1.6	6
111	Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 568-580.	3.0	198
112	Global Effects of DDX3 Inhibition on Cell Cycle Regulation Identified by a Combined Phosphoproteomics and Single Cell Tracking Approach. Translational Oncology, 2018, 11, 755-763.	1.7	21
113	Batch scheduling in the histopathology laboratory. Flexible Services and Manufacturing Journal, 2018, 30, 171-197.	1.9	5
114	Performance of 4 Immunohistochemical Phosphohistone H3 Antibodies for Marking Mitotic Figures in Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 20-26.	0.6	7
115	Ex vivo feasibility study of endoscopic intraductal laser ablation of the breast. Lasers in Surgery and Medicine, 2018, 50, 137-142.	1.1	11
116	Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment. Oncogene, 2018, 37, 63-74.	2.6	58
117	Methylation-Specific Multiplex Ligation-Dependent Probe Amplification (MS-MLPA). Methods in Molecular Biology, 2018, 1708, 537-549.	0.4	22
118	Response to A. Matikas et al Journal of the National Cancer Institute, 2018, 110, 1282-1283.	3.0	0
119	PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer. Targeted Oncology, 2018, 13, 769-777.	1.7	10
120	Comprehensive Proteomic Profiling–derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas. American Journal of Surgical Pathology, 2018, 42, 1262-1272.	2.1	3
121	E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer. Scientific Reports, 2018, 8, 15454.	1.6	55
122	αEâ€catenin is a candidate tumor suppressor for the development of Eâ€cadherinâ€expressing lobularâ€type breast cancer. Journal of Pathology, 2018, 245, 456-467.	2.1	34
123	Role of columnar cell lesions in breast carcinogenesis: analysis of chromosome 16 copy number changes by multiplex ligation-dependent probe amplification. Modern Pathology, 2018, 31, 1816-1833.	2.9	10
124	The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid cancer. Human Pathology, 2018, 81, 245-254.	1.1	14
125	Increased Levels of Oxidative Damage in Liver Metastases Compared with Corresponding Primary Colorectal Tumors. American Journal of Pathology, 2018, 188, 2369-2377.	1.9	14
126	Amide chemical exchange saturation transfer at 7ÂT: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research, 2018, 20, 51.	2.2	36

#	Article	IF	CITATIONS
127	Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study. Genes, 2018, 9, 261.	1.0	4
128	Cathepsin K associates with lymph node metastasis and poor prognosis in oral squamous cell carcinoma. BMC Cancer, 2018, 18, 385.	1.1	26
129	Fibro-osseous pseudotumor of digits - Expanding the spectrum of clonal transient neoplasms harboring USP6 rearrangement. Annals of Diagnostic Pathology, 2018, 35, 53-55.	0.6	38
130	Ethical considerations for modern molecular pathology. Journal of Pathology, 2018, 246, 405-414.	2.1	22
131	SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival. Endocrine, 2018, 62, 639-647.	1.1	9
132	Evaluating the benefits of digital pathology implementation: time savings in laboratory logistics. Histopathology, 2018, 73, 784-794.	1.6	70
133	Validation of a wholeâ€slide imageâ€based teleconsultation network. Histopathology, 2018, 73, 777-783.	1.6	17
134	Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer. Oncotarget, 2018, 9, 17078-17092.	0.8	14
135	Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer. Medical Oncology, 2017, 34, 33.	1.2	23
136	Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Modern Pathology, 2017, 30, 509-518.	2.9	32
137	Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study. Clinical Cancer Research, 2017, 23, 2730-2741.	3.2	212
138	Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol. BMC Cancer, 2017, 17, 181.	1.1	35
139	A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study. Clinical Breast Cancer, 2017, 17, 399-402.	1.1	91
140	Sequencing of DICER1 in sarcomas identifies biallelic somatic DICER1 mutations in an adult-onset embryonal rhabdomyosarcoma. British Journal of Cancer, 2017, 116, 1621-1626.	2.9	30
141	A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity. Journal of the National Cancer Institute, 2017, 109, .	3.0	30
142	Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. European Journal of Cancer, 2017, 82, 219-227.	1.3	71
143	The prognostic effect of DDX3 upregulation in distant breast cancer metastases. Clinical and Experimental Metastasis, 2017, 34, 85-92.	1.7	28
144	Moral Duties of Genomics Researchers: Why Personalized Medicine Requires a Collective Approach. Trends in Genetics, 2017, 33, 118-128.	2.9	19

#	Article	IF	Citations
145	Reliability of the Ki67-Labelling Index in Core Needle Biopsies of Luminal Breast Cancers is Unaffected by Biopsy Volume. Annals of Surgical Oncology, 2017, 24, 1251-1257.	0.7	11
146	Targeting RNA helicases in cancer: The translation trap. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 510-520.	3.3	57
147	Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients. Scientific Reports, 2017, 7, 12587.	1.6	19
148	Interlaboratory variability of Ki67 staining in breast cancer. European Journal of Cancer, 2017, 84, 219-227.	1.3	70
149	Mutational analysis using Sanger and next generation sequencing in sporadic spindle cell hemangiomas: A study of 19 cases. Genes Chromosomes and Cancer, 2017, 56, 855-860.	1.5	16
150	Correlation between E-cadherin and p120 expression in invasive ductal breast cancer with a lobular component and MRI findings. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 707-712.	1.4	7
151	Long-term prognosis of young breast cancer patients (â‰ 4 0 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. BMJ Open, 2017, 7, e017842.	0.8	11
152	Site-specific gene expression patterns in oral cancer. Head & Face Medicine, 2017, 13, 6.	0.8	19
153	Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant. Modern Pathology, 2017, 30, 15-25.	2.9	2
154	Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer. Cancer Research, 2017, 77, 623-631.	0.4	34
155	Nuclear DDX3 expression predicts poor outcome in colorectal and breast cancer. OncoTargets and Therapy, 2017, Volume 10, 3501-3513.	1.0	22
156	Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. Oncotarget, 2017, 8, 55550-55561.	0.8	14
157	Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer. PLoS ONE, 2017, 12, e0170536.	1.1	8
158	Progressive APOBEC3B mRNA expression in distant breast cancer metastases. PLoS ONE, 2017, 12, e0171343.	1.1	31
159	Unravelling site-specific breast cancer metastasis: a microRNA expression profiling study. Oncotarget, 2017, 8, 3111-3123.	0.8	24
160	Intraductal cisplatin treatment in a <i>BRCA</i> -associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. Oncotarget, 2017, 8, 60750-60763.	0.8	11
161	Prognostic modeling of oral cancer by gene profiles and clinicopathological co-variables. Oncotarget, 2017, 8, 59312-59323.	0.8	22
162	Role of DDX3 in the pathogenesis of inflammatory bowel disease. Oncotarget, 2017, 8, 115280-115289.	0.8	9

#	Article	IF	CITATIONS
163	Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: A retrospective cohort study. World Journal of Gastrointestinal Oncology, 2017, 9, 466-474.	0.8	41
164	Prophylaxis of hereditary breast cancer. Aging, 2017, 9, 2453-2454.	1.4	0
165	The Pisotriquetral Joint: Osteoarthritis and Enthesopathy. Journal of Hand and Microsurgery, 2016, 06, 18-25.	0.1	12
166	Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours. Histopathology, 2016, 69, 849-861.	1.6	21
167	Meta-analysis of the concordance of histological grade of breast cancer between core needle biopsy and surgical excision specimen. British Journal of Surgery, 2016, 103, 644-655.	0.1	27
168	Histopathology of breast cancer after magnetic resonanceâ€guided highâ€intensity focused ultrasound and radiofrequency ablation. Histopathology, 2016, 69, 250-259.	1.6	5
169	Interlaboratory Variability in the Histologic Grading of Colorectal Adenocarcinomas in a Nationwide Cohort. American Journal of Surgical Pathology, 2016, 40, 1100-1108.	2.1	14
170	Validity of whole slide images for scoring HER2 chromogenic in situ hybridisation in breast cancer. Journal of Clinical Pathology, 2016, 69, 992-997.	1.0	4
171	Predicting turnaround time reductions of the diagnostic track in the histopathology laboratory using mathematical modelling. Journal of Clinical Pathology, 2016, 69, 793-800.	1.0	6
172	p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis. Nature Communications, 2016, 7, 13874.	5.8	17
173	EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. Journal of Controlled Release, 2016, 229, 93-105.	4.8	132
174	Prognostic models in male breast cancer. Breast Cancer Research and Treatment, 2016, 160, 339-346.	1.1	4
175	Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma. Cancer Medicine, 2016, 5, 275-284.	1.3	28
176	St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods. Breast Cancer Research and Treatment, 2016, 159, 257-263.	1.1	33
177	Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer. Modern Pathology, 2016, 29, 1460-1470.	2.9	62
178	RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3. Cancer Research, 2016, 76, 6340-6350.	0.4	56
179	The reliability of histological grade in breast cancer core needle biopsies depends on biopsy size: a comparative study with subsequent surgical excisions. Histopathology, 2016, 69, 1047-1054.	1.6	24
180	Improved quality of patient care through routine second review of histopathology specimens prior to multidisciplinary meetings. Journal of Clinical Pathology, 2016, 69, 866-871.	1.0	10

#	Article	IF	Citations
181	Cytokeratin and protein expression patterns in squamous cell carcinoma of the oral cavity provide evidence for two distinct pathogenetic pathways. Oncology Letters, 2016, 12, 107-113.	0.8	34
182	FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. Molecular Diagnosis and Therapy, 2016, 20, 363-374.	1.6	17
183	Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization. EJNMMI Research, 2016, 6, 14.	1.1	43
184	Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. European Journal of Cancer, 2016, 63, 118-126.	1.3	40
185	Systematic review and meta-analysis of the diagnostic accuracy of ductoscopy in patients with pathological nipple discharge. British Journal of Surgery, 2016, 103, 632-643.	0.1	27
186	Interlaboratory variability in the grading of dysplasia in a nationwide cohort of colorectal adenomas. Histopathology, 2016, 69, 187-197.	1.6	14
187	Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 473-481.	1.4	11
188	Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer. Molecular Imaging and Biology, 2016, 18, 535-544.	1.3	54
189	First clinical experience with a dedicated MRI-guided high-intensity focused ultrasound system for breast cancer ablation. European Radiology, 2016, 26, 4037-4046.	2.3	72
190	Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. Journal of Clinical Oncology, 2016, 34, 2107-2114.	0.8	45
191	High Prevalence of MRI-Detected Contralateral and Ipsilateral Malignant Findings in Patients With Invasive Ductolobular Breast Cancer: Impact on Surgical Management. Clinical Breast Cancer, 2016, 16, 269-275.	1.1	12
192	Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review. Targeted Oncology, 2016, 11, 17-27.	1.7	24
193	Mitosis Counting in Breast Cancer: Object-Level Interobserver Agreement and Comparison to an Automatic Method. PLoS ONE, 2016, 11, e0161286.	1.1	72
194	Secretome proteomics reveals candidate non-invasive biomarkers of <i>BRCA1</i> deficiency in breast cancer. Oncotarget, 2016, 7, 63537-63548.	0.8	14
195	DNA promoter hypermethylation in nipple fluid: a potential tool for early breast cancer detection. Oncotarget, 2016, 7, 24778-24791.	0.8	24
196	Optimal endocrine therapy for breast cancer patients 45-50 years of age at diagnosis Journal of Clinical Oncology, 2016, 34, 551-551.	0.8	2
197	Targeting <scp>DDX</scp> 3 with a small molecule inhibitor for lung cancer therapy. EMBO Molecular Medicine, 2015, 7, 648-669.	3.3	189
198	Effects of magnetic resonance-guided high-intensity focused ultrasound ablation on bone mechanical properties and modeling. Journal of Therapeutic Ultrasound, 2015, 3, 13.	2.2	14

#	Article	IF	CITATIONS
199	Interventional ductoscopy in patients with pathological nipple discharge. British Journal of Surgery, 2015, 102, 1639-1648.	0.1	19
200	Impact of preoperative evaluation of tumour grade by core needle biopsy on clinical risk assessment and patient selection for adjuvant systemic treatment in breast cancer. British Journal of Surgery, 2015, 102, 1048-1055.	0.1	8
201	ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer. Journal of Cancer, 2015, 6, 1079-1086.	1.2	11
202	Expression of Connective Tissue Growth Factor in Male Breast Cancer: Clinicopathologic Correlations and Prognostic Value. PLoS ONE, 2015, 10, e0118957.	1.1	10
203	Repeated Nipple Fluid Aspiration: Compliance and Feasibility Results from a Prospective Multicenter Study. PLoS ONE, 2015, 10, e0127895.	1.1	11
204	Chromosome 17 copy number changes in male breast cancer. Cellular Oncology (Dordrecht), 2015, 38, 237-245.	2.1	12
205	The diagnostic process of cervical cancer; areas of good practice, and windows of opportunity. Gynecologic Oncology, 2015, 138, 405-410.	0.6	2
206	Prediction of positive resection margins in patients with non-palpable breast cancer. European Journal of Surgical Oncology, 2015, 41, 106-112.	0.5	30
207	Sentinel lymph node localization with contrast-enhanced ultrasound and an I-125 seed: An ideal prospective development study. International Journal of Surgery, 2015, 14, 1-6.	1.1	16
208	Brief fixation does not hamper the reliability of Ki67 analysis in breast cancer coreâ€needle biopsies: a doubleâ€centre study. Histopathology, 2015, 66, 380-387.	1.6	6
209	Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment. European Journal of Cancer, 2015, 51, 915-921.	1.3	41
210	Promoter hypermethylation profiling of distant breast cancer metastases. Breast Cancer Research and Treatment, 2015, 151, 41-55.	1.1	11
211	Tracing differences between male and female breast cancer: both diseases own a different biology. Histopathology, 2015, 67, 888-897.	1.6	16
212	Methylation biomarkers for pleomorphic lobular breast cancer - a short report. Cellular Oncology (Dordrecht), 2015, 38, 397-405.	2.1	10
213	DDX3 has divergent roles in head and neck squamous cell carcinomas in smokingversusnon-smoking patients. Oral Diseases, 2015, 21, 270-271.	1.5	16
214	St. Gallen endocrine response classes predict recurrence rates over time. Breast, 2015, 24, 705-712.	0.9	5
215	Copy number profiling by array comparative genomic hybridization identifies frequently occurring <scp>BRCA</scp> 2â€like male breast cancer. Genes Chromosomes and Cancer, 2015, 54, 734-744.	1.5	10
216	Bone metastasis treatment using magnetic resonance-guided high intensity focused ultrasound. Bone, 2015, 81, 513-523.	1.4	25

#	Article	IF	Citations
217	Hypoxia-inducible factor $1-\hat{l}\pm$ in chronic gastrointestinal ischemia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 125-132.	1.4	5
218	Assessment of algorithms for mitosis detection in breast cancer histopathology images. Medical Image Analysis, 2015, 20, 237-248.	7.0	338
219	Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer. Oncotarget, 2015, 6, 28312-28326.	0.8	79
220	miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers. Oncotarget, 2015, 6, 32115-32137.	0.8	20
221	Same-Day Diagnosis Based on Histology for Women Suspected of Breast Cancer: High Diagnostic Accuracy and Favorable Impact on the Patient. PLoS ONE, 2014, 9, e103105.	1.1	17
222	SlideToolkit: An Assistive Toolset for the Histological Quantification of Whole Slide Images. PLoS ONE, 2014, 9, e110289.	1.1	23
223	The Effects of Under 6 Hours of Formalin Fixation on Hormone Receptor and HER2 Expression in Invasive Breast Cancer. American Journal of Clinical Pathology, 2014, 142, 16-22.	0.4	22
224	Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. BMC Cancer, 2014, 14, 864.	1.1	32
225	The value of autopsies in the era of high-tech medicine: discrepant findings persist. Journal of Clinical Pathology, 2014, 67, 512-519.	1.0	77
226	Do columnar cell lesions exist in the male breast?. Histopathology, 2014, 64, 818-825.	1.6	8
227	Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes. Cancer Letters, 2014, 344, 138-146.	3.2	34
228	Analysis of gene copy number alterations by multiplex ligation-dependent probe amplification in columnar cell lesions of the breast. Cellular Oncology (Dordrecht), 2014, 37, 147-154.	2.1	13
229	Promoter hypermethylation using 24-gene array in early head and neck cancer. Epigenetics, 2014, 9, 1220-1227.	1.3	24
230	Corrections to "Breast cancer histopathology image analysis: A review―[May 14 1400-1411]. IEEE Transactions on Biomedical Engineering, 2014, 61, 2819-2819.	2.5	4
231	Radiofrequency ablation of small breast tumours: Evaluation of a novel bipolar cool-tip application. European Journal of Surgical Oncology, 2014, 40, 1222-1229.	0.5	24
232	Clonal intratumor heterogeneity of promoter hypermethylation in breast cancer by MS-MLPA. Modern Pathology, 2014, 27, 869-874.	2.9	20
233	Whole slide images for primary diagnostics of urinary system pathology: a feasibility study. Journal of Renal Injury Prevention, 2014, 3, 91-6.	0.6	24
234	Tablet, Web-Based, or Paper Questionnaires for Measuring Anxiety in Patients Suspected of Breast Cancer: Patients' Preferences and Quality of Collected Data. Journal of Medical Internet Research, 2014, 16, e239.	2.1	36

#	Article	IF	CITATIONS
235	Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imaging. Cellular Oncology (Dordrecht), 2013, 36, 333-340.	2.1	6
236	CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Research and Treatment, 2013, 139, 649-655.	1.1	21
237	Discrepancy between routine and expert pathologists' assessment of non-palpable breast cancer and its impact on locoregional and systemic treatment. European Journal of Pharmacology, 2013, 717, 31-35.	1.7	8
238	The effects of magnetic resonance imaging-guided high-intensity focused ultrasound ablation on human cadaver breast tissue. European Journal of Pharmacology, 2013, 717, 21-30.	1.7	7
239	Comparative immunohistochemical investigation of rat and human hepatocellular carcinomas. Journal of Histotechnology, 2013, 36, 75-85.	0.2	0
240	Going fully digital: Perspective of a Dutch academic pathology lab. Journal of Pathology Informatics, 2013, 4, 15.	0.8	135
241	Whole slide images for primary diagnostics of paediatric pathology specimens: a feasibility study. Journal of Clinical Pathology, 2013, 66, 218-223.	1.0	33
242	Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. Annals of Oncology, 2013, 24, 3017-3023.	0.6	47
243	FER kinase promotes breast cancer metastasis by regulating $\hat{l}\pm 6$ - and \hat{l}^21 -integrin-dependent cell adhesion and anoikis resistance. Oncogene, 2013, 32, 5582-5592.	2.6	58
244	Differential Expression of Growth Factor Receptors and Membrane-Bound Tumor Markers for Imaging in Male and Female Breast Cancer. PLoS ONE, 2013, 8, e53353.	1.1	18
245	Prognostic Value of Mitotic Index and Bcl2 Expression in Male Breast Cancer. PLoS ONE, 2013, 8, e60138.	1.1	8
246	Evaluation of Mitotic Activity Index in Breast Cancer Using Whole Slide Digital Images. PLoS ONE, 2013, 8, e82576.	1.1	46
247	ESR1 Amplification in Breast Cancer by Optimized RNase FISH: Frequent but Low-Level and Heterogeneous. PLoS ONE, 2013, 8, e84189.	1.1	14
248	Expression of the RNA Helicase DDX3 and the Hypoxia Response in Breast Cancer. PLoS ONE, 2013, 8, e63548.	1.1	49
249	Chromosome 16q lossa genetic key to the understanding of breast carcinogenesis. Histology and Histopathology, 2013, 28, 311-20.	0.5	12
250	Cost-effectiveness of adjuvant systemic therapy in low-risk breast cancer patients with nodal isolated tumor cells or micrometastases. Annals of Oncology, 2012, 23, 2585-2591.	0.6	1
251	Molecular subtyping of male breast cancer by immunohistochemistry. Modern Pathology, 2012, 25, 398-404.	2.9	113
252	Relevant impact of central pathology review on nodal classification in individual breast cancer patients. Annals of Oncology, 2012, 23, 2561-2566.	0.6	29

#	Article	IF	CITATIONS
253	Whole slide images for primary diagnostics in dermatopathology: a feasibility study. Journal of Clinical Pathology, 2012, 65, 152-158.	1.0	69
254	Epigenetic biomarkers in the diagnosis of ovarian cancer. Expert Opinion on Medical Diagnostics, 2012, 6, 421-438.	1.6	6
255	Whole slide images as a platform for initial diagnostics in histopathology in a medium-sized routine laboratory. Journal of Clinical Pathology, 2012, 65, 1107-1111.	1.0	55
256	Immunophenotyping of male breast cancer. Histopathology, 2012, 61, 1145-1155.	1.6	31
257	Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Research and Treatment, 2012, 135, 49-58.	1.1	53
258	Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer. Breast Cancer Research and Treatment, 2012, 136, 705-715.	1.1	44
259	HIF- $1\hat{l}\pm$ and NOTCH signaling in ductal and lobular carcinomas of the breast. Cellular Oncology (Dordrecht), 2012, 35, 435-442.	2.1	12
260	Whole slide images for primary diagnostics of gastrointestinal tract pathology: a feasibility study. Human Pathology, 2012, 43, 702-707.	1.1	76
261	Immunophenotyping invasive breast cancer: paving the road for molecular imaging. BMC Cancer, 2012, 12, 240.	1.1	22
262	Digital slide images for primary diagnostics in breast pathology: a feasibility study. Human Pathology, 2012, 43, 2318-2325.	1.1	58
263	Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer, 2012, 118, 4929-4935.	2.0	81
264	Digital pathology: current status and future perspectives. Histopathology, 2012, 61, 1-9.	1.6	285
265	Association of the phosphorylation of the estrogen receptor at serine 118 and 167 with prognosis in postmenopausal breast cancer patients Journal of Clinical Oncology, 2012, 30, 562-562.	0.8	0
266	HER-2/ <i>neu</i> Testing and Therapy in Gastroesophageal Adenocarcinoma. Pathology Research International, 2011, 2011, 1-10.	1.4	35
267	Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer. Cellular Oncology (Dordrecht), 2011, 34, 3-10.	2.1	25
268	Pathology of hereditary breast cancer. Cellular Oncology (Dordrecht), 2011, 34, 71-88.	2.1	123
269	Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF- $1\hat{l}\pm$ expression. Cellular Oncology (Dordrecht), 2011, 34, 565-570.	2.1	20
270	Progression risk of columnar cell lesions of the breast diagnosed in core needle biopsies. International Journal of Cancer, 2011, 129, 2674-2680.	2.3	17

#	Article	IF	CITATIONS
271	The role of hypoxia inducible factor-1alpha in gynecological cancer. Critical Reviews in Oncology/Hematology, 2011, 78, 173-184.	2.0	73
272	Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer. Breast Cancer Research and Treatment, 2010, 121, 35-40.	1.1	13
273	Expression of the stem cell marker ALDH1 in the normal breast of BRCA1 mutation carriers. Breast Cancer Research and Treatment, 2010, 123, 611-612.	1.1	12
274	Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer. Familial Cancer, 2010, 9, 321-325.	0.9	22
275	Molecular Differences between Ductal Carcinoma <i>In Situ</i> and Adjacent Invasive Breast Carcinoma: A Multiplex Ligation-Dependent Probe Amplification Study. Analytical Cellular Pathology, 2010, 33, 165-173.	0.7	21
276	ESR1 Amplification is Rare in Breast Cancer and is Associated with High Grade and High Proliferation: A Multiplex Ligation-Dependent Probe Amplification Study. Analytical Cellular Pathology, 2010, 33, 13-18.	0.7	16
277	Low Levels of (i>BNIP3 < /i>Promoter Hypermethylation in Invasive Breast Cancer. Analytical Cellular Pathology, 2010, 33, 175-176.	0.7	6
278	Pathology Issues Related to SN Procedures and Increased Detection of Micrometastases and Isolated Tumor Cells. Breast Disease, 2010, 31, 65-81.	0.4	10
279	Hypoxia-Inducible Factor-1 as a Therapeutic Target in Endometrial Cancer Management. Obstetrics and Gynecology International, 2010, 2010, 1-8.	0.5	18
280	Creation of a fully digital pathology slide archive by high-volume tissue slide scanning. Human Pathology, 2010, 41, 751-757.	1.1	92
281	Validation of a Fully Automated HER2 Staining Kit in Breast Cancer. Analytical Cellular Pathology, 2010, 32, 149-155.	0.7	1
282	Multiplex Ligation-Dependent Probe Amplification to Detect HER2 Amplification in Breast Cancer: New Insights in Optimal Cut-Off Value. Analytical Cellular Pathology, 2010, 32, 311-312.	0.7	1
283	Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax) Tj ETQq1 1 sentinel lymph node (SN): Results from the MIRROR study. Journal of Clinical Oncology, 2009, 27, CRA506-CRA506.	0.784314 0.8	rgBT /Ove <mark>rl</mark> d
284	Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax) Tj ETQq0 0 sentinel lymph node (SN): Results from the MIRROR study. Journal of Clinical Oncology, 2009, 27, CRA506-CRA506.	0 rgBT /0 0.8	verlock 10 Tf 10
285	HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization. Analytical Cellular Pathology, 2009, 31, 1-10.	0.7	2
286	Genomic Profiling by Array Comparative Genomic Hybridization Reveals Novel DNA Copy Number Changes in Breast Phyllodes Tumours. Analytical Cellular Pathology, 2009, 31, 31-39.	0.7	1
287	Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax) Tj ETQq1 1 sentinel lymph node (SN): Results from the MIRROR study. Journal of Clinical Oncology, 2009, 27,	0.784314 0.8	rgBT /Overlo
288	CRA506-CRÁ506. High frequency of HIF-1α overexpression in BRCA1 related breast cancer. Breast Cancer Research and Treatment, 2008, 111, 475-480.	1.1	74

#	Article	IF	Citations
289	Hypoxiaâ€inducible factor 1α is essential for hypoxic p27 induction in endometrioid endometrial carcinoma. Journal of Pathology, 2008, 214, 38-45.	2.1	25
290	The Microanatomic Location of Metastatic Breast Cancer in Sentinel Lymph Nodes Predicts Nonsentinel Lymph Node Involvement. Annals of Surgical Oncology, 2008, 15, 1309-1315.	0.7	20
291	Fluorescent stains for quantification of DNA by confocal laser scanning microscopy in 3-D. Biotechnic and Histochemistry, 2008, 83, 63-69.	0.7	25
292	Molecular Analysis of Nipple Fluid for Breast Cancer Screening. Pathobiology, 2008, 75, 149-152.	1.9	26
293	Conditional Inactivation of HIF-1 Using Intrabodies. Analytical Cellular Pathology, 2008, 30, 397-409.	0.7	2
294	Oxytocin: bringing magic into nipple aspiration. Annals of Oncology, 2007, 18, 1743-1744.	0.6	18
295	Re: Tissue Banks Trigger Worry About Ownership Issues. Journal of the National Cancer Institute, 2007, 99, 253-253.	3.0	0
296	The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. European Journal of Cancer, 2007, 43, 527-535.	1.3	28
297	The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Human Pathology, 2007, 38, 1232-1238.	1.1	46
298	A restaining method to restore faded fluorescence in tissue specimens for quantitative confocal microscopy. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2007, 71A, 875-881.	1.1	3
299	Discrimination between benign and malignant prostate tissue using chromatin texture analysis in 3-D by confocal laser scanning microscopy. Prostate, 2007, 67, 248-254.	1.2	31
300	BRCA1 and BRCA2 germline mutation analysis in the Indonesian population. Breast Cancer Research and Treatment, 2007, 106, 297-304.	1.1	56
301	Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neuamplification in invasive breast cancer. Biotechnic and Histochemistry, 2006, 81, 79-85.	0.7	20
302	p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancerâ [†] t. Human Pathology, 2006, 37, 1085-1092.	1.1	54
303	Confocal 3D DNA Cytometry: Assessment of Required Coefficient of Variation by Computer Simulation. Analytical Cellular Pathology, 2006, 28, 123-123.	0.7	0
304	Prospective Multicenter Validation of the Independent Prognostic Value of the Mitotic Activity Index in Lymph Node–Negative Breast Cancer Patients Younger Than 55 Years. Journal of Clinical Oncology, 2005, 23, 5993-6001.	0.8	94
305	Prognostic value of proliferation in invasive breast cancer: a review. Journal of Clinical Pathology, 2004, 57, 675-681.	1.0	299
306	Cadaveric tissue donation: a pathologist's perspective. Journal of Medical Ethics, 2003, 29, 135-136.	1.0	5

#	Article	IF	Citations
307	For and against: No consent should be needed for using leftover body material for scientific purposes * For * Against. BMJ: British Medical Journal, 2002, 325, 648-651.	2.4	221
308	No consent should be needed for using leftover body material for scientific purposes. For. BMJ, The, 2002, 325, 648-51.	3.0	101
309	Tubal ligation and risk of ovarian cancer. Lancet, The, 2001, 358, 844.	6.3	64
310	Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. Journal of Pathology, 2001, 195, 451-456.	2.1	681
311	Reliability of the Sentinel Node Procedure in Melanoma Patients: Analysis of Failures After Long-Term Follow-Up. Annals of Surgical Oncology, 2000, 7, 461-468.	0.7	81
312	Prolonged Neoadjuvant Chemotherapy with GMâ€CSF in Locally Advanced Breast Cancer. Oncologist, 1999, 4, 106-111.	1.9	36
313	Are Locoregional Cutaneous Metastases in Melanoma Predictable?. Annals of Surgical Oncology, 1999, 6, 315-321.	0.7	83
314	Ultrasound-guided lumpectomy of nonpalpable breast cancers: A feasibility study looking at the accuracy of obtained margins., 1999, 72, 72-76.		80
315	Relationships between vascularization and proliferation in invasive breast cancer., 1999, 189, 309-318.		45
316	Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors. Journal of Pathology, 1998, 186, 356-362.	2.1	62
317	Pathology of silicone leakage from breast implants. Journal of Clinical Pathology, 1998, 51, 493-497.	1.0	97
318	Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors., 1998, 186, 356.		1
319	Origins of image analysis in clinical pathology Journal of Clinical Pathology, 1997, 50, 365-370.	1.0	53
320	Effects of Chemotherapy on Pathologic and Biologic Characteristics of Locally Advanced Breast Cancer. American Journal of Clinical Pathology, 1997, 107, 211-218.	0.4	104
321	Counting mitoses by image processing in Feulgen stained breast cancer sections: The influence of resolution. Cytometry, 1997, 28, 135-140.	1.8	36
322	Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: Classical and random mitotic activity assessments with correction for volume percentage of epithelium. Human Pathology, 1995, 26, 1086-1092.	1.1	60
323	Reproducibility of mitosis counting in 2,469 breast cancer specimens: Results from the Multicenter Morphometric Mammary Carcinoma Project. Human Pathology, 1992, 23, 603-607.	1.1	326
324	The Multicenter Morphometric Mammary Carcinoma Project (MMMCP). Pathology Research and Practice, 1989, 185, 664-670.	1.0	51